{"id":17599,"date":"2016-02-25T00:00:00","date_gmt":"2016-02-25T00:00:00","guid":{"rendered":"https:\/\/cadca1stg.wpengine.com\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/"},"modified":"2016-02-25T00:00:00","modified_gmt":"2016-02-25T00:00:00","slug":"fda-top-officials-call-for-review-of-agency-opioid-policies","status":"publish","type":"resource","link":"https:\/\/www.cadca.org\/fr\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/","title":{"rendered":"FDA Top Officials Call for Review of Agency Opioid Policies"},"content":{"rendered":"<p>In response to the opioid abuse epidemic, Dr. Robert Califf, the Food and Drug Administration\u2019s Deputy Commissioner for Medical Products and Tobacco, along with other FDA leaders, called for a far-reaching action plan to reassess the agency\u2019s approach to opioid medications. The plan will focus on policies aimed at reversing the epidemic, while still providing patients in pain access to effective relief.<\/p>\n<p>The FDA will:<\/p>\n<ul>\n<li>Re-examine the risk-benefit paradigm for opioids and ensure that the agency considers their wider public health effects<\/li>\n<li>Convene an expert advisory committee before approving any new drug application for an opioid that does not have abuse-deterrent properties;<\/li>\n<li>Assemble and consult with the Pediatric Advisory Committee regarding a framework for pediatric opioid labeling before any new labeling is approved;\u00a0<\/li>\n<li>Develop changes to immediate-release opioid labeling, including additional warnings and safety information that incorporate elements similar to the extended-release\/long-acting (ER\/LA) opioid analgesics labeling that is currently required;<\/li>\n<li>Update Risk Evaluation and Mitigation Strategy requirements for opioids after considering advisory committee recommendations and review of existing requirements;<\/li>\n<li>Expand access to, and encourage the development of, abuse-deterrent formulations of opioid products;<\/li>\n<li>Improve access to naloxone and medication-assisted treatment options for patients with\u00a0 opioid use disorders; and<\/li>\n<li>Support better pain management options, including alternative treatments.<\/li>\n<\/ul>\n<p>As one of the cornerstones of this plan, the FDA will seek guidance from outside experts in the fields of pain management and drug abuse. For example, the FDA has already asked the National Academies of Sciences, Engineering, and Medicine to help develop a framework for opioid review, approval and monitoring that balances individual need for pain control with considerations of the broader public health consequences of opioid misuse and abuse.<\/p>\n<p>\u201cWe are determined to help defeat this epidemic through a science-based and continuously evolving approach,\u201d Califf said in a news release. \u201cThis plan contains real measures this agency can take to make a difference in the lives of so many people who are struggling under the weight of this terrible crisis.\u201d<\/p>","protected":false},"excerpt":{"rendered":"<p>In response to the opioid abuse epidemic, Dr. Robert Califf, the Food and Drug Administration\u2019s Deputy Commissioner for Medical Products<\/p>","protected":false},"author":23,"featured_media":0,"template":"","resource_type":[281],"drug_specific_issues":[307],"action_to_do":[],"class_list":["post-17599","resource","type-resource","status-publish","hentry","resource_type-coalitions-online","drug_specific_issues-prescription-and-over-the-counter-medications"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Top Officials Call for Review of Agency Opioid Policies | CADCA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cadca.org\/fr\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Top Officials Call for Review of Agency Opioid Policies | CADCA\" \/>\n<meta property=\"og:description\" content=\"In response to the opioid abuse epidemic, Dr. Robert Califf, the Food and Drug Administration\u2019s Deputy Commissioner for Medical Products\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cadca.org\/fr\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/\" \/>\n<meta property=\"og:site_name\" content=\"CADCA\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/cadca-member-of-logo1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"880\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-top-officials-call-for-review-of-agency-opioid-policies\\\/\",\"url\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-top-officials-call-for-review-of-agency-opioid-policies\\\/\",\"name\":\"FDA Top Officials Call for Review of Agency Opioid Policies | CADCA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cadca.org\\\/#website\"},\"datePublished\":\"2016-02-25T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-top-officials-call-for-review-of-agency-opioid-policies\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-top-officials-call-for-review-of-agency-opioid-policies\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-top-officials-call-for-review-of-agency-opioid-policies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cadca.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Top Officials Call for Review of Agency Opioid Policies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/#website\",\"url\":\"https:\\\/\\\/www.cadca.org\\\/\",\"name\":\"CADCA\",\"description\":\"The Premier Prevention Association\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cadca.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Top Officials Call for Review of Agency Opioid Policies | CADCA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cadca.org\/fr\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/","og_locale":"fr_FR","og_type":"article","og_title":"FDA Top Officials Call for Review of Agency Opioid Policies | CADCA","og_description":"In response to the opioid abuse epidemic, Dr. Robert Califf, the Food and Drug Administration\u2019s Deputy Commissioner for Medical Products","og_url":"https:\/\/www.cadca.org\/fr\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/","og_site_name":"CADCA","og_image":[{"width":880,"height":500,"url":"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/cadca-member-of-logo1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cadca.org\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/","url":"https:\/\/www.cadca.org\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/","name":"FDA Top Officials Call for Review of Agency Opioid Policies | CADCA","isPartOf":{"@id":"https:\/\/www.cadca.org\/#website"},"datePublished":"2016-02-25T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.cadca.org\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cadca.org\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cadca.org\/resource\/fda-top-officials-call-for-review-of-agency-opioid-policies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cadca.org\/"},{"@type":"ListItem","position":2,"name":"FDA Top Officials Call for Review of Agency Opioid Policies"}]},{"@type":"WebSite","@id":"https:\/\/www.cadca.org\/#website","url":"https:\/\/www.cadca.org\/","name":"CADCA","description":"The Premier Prevention Association","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cadca.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/resource\/17599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/resource"}],"about":[{"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/types\/resource"}],"author":[{"embeddable":true,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/users\/23"}],"version-history":[{"count":0,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/resource\/17599\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/media?parent=17599"}],"wp:term":[{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/resource_type?post=17599"},{"taxonomy":"drug_specific_issues","embeddable":true,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/drug_specific_issues?post=17599"},{"taxonomy":"action_to_do","embeddable":true,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/action_to_do?post=17599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}